| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Operating Expenses: | |||||||||
Revenues | |||||||||
- | - | - | - | 22,487 | 17,938 | 14,668 | 14,329 | 10,050 | 181 |
Cost of revenues | |||||||||
- | - | - | - | 20,158 | 15,678 | 12,947 | 11,949 | 8,646 | 0 |
Gross profit | |||||||||
- | - | - | - | - | - | - | - | 1,403 | 181 |
Research and development | |||||||||
10,797 | 7,594 | 15,843 | 16,699 | 23,899 | 29,194 | 16,917 | 10,451 | 7,720 | 6,008 |
Impairment of goodwill and intangible assets | |||||||||
- | - | - | - | 62,273 | - | - | - | - | - |
Impairment of Intangible Assets, Finite-lived | |||||||||
- | - | - | - | - | 0 | 0 | - | - | - |
General and administrative | |||||||||
9,295 | 9,393 | 11,750 | 12,802 | 30,005 | 30,806 | 21,612 | 22,315 | 27,687 | 19,468 |
Goodwill impairment | |||||||||
- | - | - | - | - | - | - | - | - | 558 |
Total operating expenses | |||||||||
20,092 | 16,987 | 27,593 | 29,501 | 136,336 | 75,679 | 51,477 | 44,715 | 35,407 | 26,034 |
Operating loss | |||||||||
-20,092 | -16,987 | -27,593 | -29,501 | -113,849 | -57,740 | -36,808 | -30,385 | -34,004 | -25,853 |
Other income: | |||||||||
Investment income, net | |||||||||
740 | 824 | 273 | 23 | 17,723 | 2,926 | -1,614 | -4,314 | 2,085 | 333 |
Interest expense | |||||||||
0 | 5 | 378 | 1,779 | 2,128 | 755 | 281 | 1,576 | 2,647 | 289 |
Total other income | |||||||||
740 | 819 | -105 | -1,755 | 15,595 | 2,170 | -1,896 | -5,891 | -561 | 44 |
Loss before benefit from income taxes and noncontrolling interests | |||||||||
- | - | -27,698 | -31,257 | -98,254 | -55,570 | -38,705 | -36,276 | -34,566 | -25,809 |
Income Tax Expense (Benefit) | |||||||||
- | - | -11,527 | 0 | -17,243 | -104 | 780 | -175 | 0 | - |
Net loss from continuing operations | |||||||||
- | - | -16,171 | -31,257 | - | - | - | -36,101 | -34,566 | - |
Loss on exit of segment | |||||||||
- | - | - | - | - | - | - | -30,267 | - | - |
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | |||||||||
- | - | 38,399 | -2,051 | - | - | - | - | -22,016 | 6,412 |
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | |||||||||
-19,352 | -16,168 | 22,228 | -33,309 | -81,010 | -55,466 | -39,485 | -66,369 | -56,582 | -19,397 |
Less - net income attributable to noncontrolling interests | |||||||||
9 | -1 | -182 | -241 | -124 | -593 | -504 | -287 | -299 | 0 |
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders | |||||||||
-19,361 | -16,167 | 22,979 | -32,656 | - | - | - | -53,769 | -47,134 | -23,305 |
Less - net loss from discontinued operations attributable to noncontrolling interests | |||||||||
- | - | -569 | -411 | - | - | - | -12,312 | -9,148 | 3,908 |
Warrant inducements | |||||||||
- | - | - | - | - | - | - | 1,012 | 0 | - |
Redeemable Preferred Stock Dividends | |||||||||
- | - | - | - | - | - | - | 528 | - | - |
Warrant inducements | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Preferred dividends | |||||||||
- | - | - | - | - | - | - | - | 639 | 237 |
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders | |||||||||
- | - | - | - | -80,885 | -54,872 | -38,981 | -55,310 | -47,774 | -23,543 |
Basic and diluted loss per share | |||||||||
Preferred dividends | |||||||||
- | - | - | - | - | - | - | - | 639 | 237 |
Loss from continuing operations | |||||||||
- | - | -15,989 | -31,015 | - | - | - | -35,814 | -34,266 | -25,809 |
Income from discontinued operations - net of taxes | |||||||||
- | - | 38,968 | -1,640 | - | - | - | -17,955 | -12,867 | 2,503 |
Net income (loss) attributable to Caladrius Biosciences, Inc. common shareholders | |||||||||
-19,361 | -16,167 | 22,979 | -32,656 | - | - | - | - | - | - |
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders | |||||||||
- | - | - | - | - | - | - | -55,310 | -47,774 | -23,543 |
Basic and diluted loss per share: | |||||||||
Continuing operations (USD per share) | |||||||||
- | - | -1.78 | -4.74 | - | - | - | - | - | - |
Discontinued operations (USD per share) | |||||||||
- | - | 4.34 | -0.25 | - | - | - | - | - | - |
Caladrius Biosciences, Inc. common shareholders (USD per share) | |||||||||
- | - | 2.56 | -4.99 | - | - | - | - | - | - |
Continuing operations (USD per share) | |||||||||
- | - | - | -4.74 | - | - | - | - | - | - |
Discontinued operations (USD per share) | |||||||||
- | - | - | -0.25 | - | - | - | - | - | - |
Caladrius Biosciences, Inc. common shareholders (USD per share) | |||||||||
- | - | - | -4.99 | - | - | - | - | - | - |
Continuing operations (in usd per share) | |||||||||
- | - | - | - | - | - | - | -2.59 | -0.39 | -0.50 |
Discontinued operations (in usd per share) | |||||||||
- | - | - | - | - | - | - | -1.30 | -0.15 | - |
Discontinued operations | |||||||||
- | - | - | - | - | - | - | - | - | 0.05 |
Caladrius Biosciences, Inc. common stockholders (in usd per share) | |||||||||
-1.88 | -1.67 | - | - | -16.67 | -1.68 | -1.90 | -4.00 | -0.54 | -0.46 |
Weighted average common shares outstanding | |||||||||
Basic shares | |||||||||
- | - | 8,969 | 6,548 | - | - | - | - | - | - |
Diluted shares | |||||||||
- | - | 8,969 | 6,548 | - | - | - | - | - | - |
Weighted average common shares outstanding (in shares) | |||||||||
- | - | - | - | 4,850 | 32,756 | 20,495 | 13,841 | 88,598 | 51,632 |
Basic and diluted shares | |||||||||
10,325 | 9,689 | - | - | - | - | - | - | - | - |